Tirzepatide for Hormone Balance: What the Evidence Shows
What human and animal studies show about Tirzepatide for hormone balance, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 6
- PubMed records, our ledger
- Animal studies
- 4
- PubMed records, our ledger
- Studies we summarised
- 1
- with an outcome for hormone balance
Evidence for hormone balance
Each row is an outcome related to hormone balance from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Gonadal hormones and sexual function | After 2 months, the tirzepatide group had greater reductions in body weight, waist circumference, binge-eating score and fat mass and a notable increase in lean mass and erectile-function score than the other groups (small pilot). | Human controlled trialn = 83 | Reproductive biology and endocrinology 2025, PMID 40604795 |
| Testosterone and gonadotropins | The tirzepatide group had higher LH, FSH, SHBG, total, free and bioavailable testosterone and lower estradiol than both comparison groups. | Human controlled trialn = 83 | Reproductive biology and endocrinology 2025, PMID 40604795 |
PubMed records for Tirzepatide and hormone balance: 6 human, 4 animal (search counts, not studies we reviewed). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
What hormones are
MedlinePlus says hormones affect many processes, including growth, metabolism, sexual function, reproduction and mood.[2]
Hormone outcomes in people treated with tirzepatide
In a controlled pilot of men with obesity and metabolic hypogonadism, the tirzepatide group had higher LH, FSH, SHBG and testosterone levels, and lower estradiol, than both comparison groups after 2 months.[1]
The pilot enrolled 83 patients with obesity, with a mean age of 55.3 years.[1]
The tirzepatide group started at 2.5 mg weekly for the first month and moved to 5 mg from the second month.[1]
The goal ledger for tirzepatide and hormone balance (PubMed, 2026-10-02) found 17 records, of which 7 indexed as human, 4 as animal-only and 0 as randomised trials.
Calculated from query (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab]) AND (estrogen*[tiab] OR oestrogen*[tiab] OR estradiol[tiab] OR oestradiol[tiab] OR progesterone[tiab] OR "sex hormone"[tiab] OR "sex hormones"[tiab] OR "hormone balance"[tiab] OR "hormonal balance"[tiab] OR "hormonal imbalance"[tiab]); date 2026-10-02; all 17; human 7; animal 4; rct 0; source our PubMed count ledger ledger. Formula: counts as returned by the dated PubMed query and its filters
Label warning tied to hormones
The Mounjaro label advises people on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose escalation.[3]
Other peptides people research for hormone balance
All peptides for hormone balance, comparedCommon questions
Does Tirzepatide help with hormone balance?
The strongest study we summarise for hormone balance is human rct evidence, across 1 study with an outcome for hormone balance. A trial result is not an approval; see the legal status.
Is Tirzepatide approved for hormone balance?
Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for hormone balance?
There is no single answer. Our hormone balance overview compares each candidate by evidence grade and legal status rather than by popularity.
Does tirzepatide change hormones?
In the only controlled study cited, in men with obesity, testosterone, LH and FSH rose and estradiol fell in the tirzepatide group; the authors call the study a pilot.[1]
More on Tirzepatide
Sources
- 1Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.Reproductive biology and endocrinology : RB&E · 2025PMID 40604795Accessed 2 Oct 2026
- 2Official web pageOfficial web page · web page
- 3MOUNJARO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.